社区

Omaha, NE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), developer of patented technology that works as a safe and low-cost replac

Aviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy ; AVD-104 is currently enrolling patients with GA in the SIGLEC Phase 2/3 Trial.A multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema . AVD-104 is an engineered glycan nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated ret

12月17日，$瑞幸咖啡(LK)$在美国粉单市场盘前大涨44%。老虎综合账户可以交易在粉单市场的瑞幸咖啡股票。 美国证券交易委员会（SEC）发布消息称，与$瑞幸咖啡(LK)$达成和解，后者同意针对造假指控支付1.8亿美元（约合人民币11.8亿元）罚款。 SEC表示，从2019年4月至2020年1月，瑞幸通过关联方虚假交易伪造了超过3亿美元的销售额，从债券和股票投资者那里筹集了超过8.64亿美元资金。不过，这项和解协议需要得到法院的同意才能生效。 截至目前，瑞幸面临的各项处罚总金额超过12亿元人民币。

苹果已经处于高利润、高市值和不能冒险大创新夹层的危险处境里。

美东时间10月7日晚9时许，美国副总统彭斯和民主党副总统候选人卡玛拉·哈里斯在盐湖城犹他大学举行首场、也是唯一一场副总统候选人电视辩论。辩论由《今日美国》华盛顿分社社长苏珊·佩奇主持。整个辩论围绕新冠